Kia President and CEO Ho Sung Song honored at 2025 Autocar Awards
– President and CEO Ho Sung Song awarded with Autocar's highest accolade, the Issigonis Trophy, in recognition of his significant contributions to the global automotive industry
– Honored for positioning Kia at the forefront of electrification and steering the mobility industry toward a smarter future with new PBV vision
– Kia EV3 named as 'Best Electric Car' by Autocar on account of its compelling space and practicality, rapid charging speed and convincing electric range
SEOUL, South Korea, June 25, 2025 /PRNewswire/ — Kia Corporation (Kia) President and CEO Ho Sung Song has been honored with the prestigious Issigonis Trophy at the 2025 Autocar Awards.
Named after the legendary automotive designer and inventor Sir Alec Issigonis, the Trophy is Autocar's most prestigious award. Presented annually, it recognizes individuals who have made a significant contribution to the automotive industry through innovation, leadership and exceptional business performance.
Mark Tisshaw, Editor of Autocar, commented, 'We're delighted to present Ho Sung Song with the Issigonis Trophy. We've been hugely impressed by the way Mr Song has led Kia and the success he has achieved for the company and its continued growth. He has championed great design and improved branding and confronted the challenge of electrification by making ever better and ever more desirable cars that are among the industry's very best.'
On receiving the Issigonis Trophy, President Song remarked, 'It is a great honor to receive this year's Issigonis Trophy. I would like to express my sincere thanks to the Autocar team for this recognition — not just of me, but of the incredible Kia team worldwide, whose dedication and belief in our mission continue to drive the brand forward.'
He continued, 'Our commitment remains clear. To design with intention, to lead with responsibility, and to continue delivering experiences that inspire. We accept it with gratitude — and vow to keep pushing boundaries with purpose.'
Kia under President Ho Sung Song's leadership
Since his appointment as President of Kia in 2020, President Song has led a successful transformation of the company. Under his leadership, Kia's mid- to long-term 'Plan S' strategy has progressively positioned the brand as a global leader in electrification and sustainable mobility solutions.
A key part of this transformation has been the global roll-out of Kia's new brand identity and the launch of an award-winning range of hybrid and electric vehicles. These include the Kia EV9, named World Car of the Year in 2024, and the EV3, which was awarded both World Car of the Year and UK Car of the Year in 2025.
Kia has also taken a pioneering approach to the commercial vehicle market with its revolutionary Platform Beyond Vehicle (PBV) strategy, a core element of 'Plan S'. In 2024, Kia unveiled its PBV concept range at CES in Las Vegas and announced the development of a dedicated PBV factory in Korea. Built for business, Kia's first dedicated all electric commercial vehicle, the PV5, is planned to launch in global markets this year. Kia plans to sell 250,000 PBVs globally in 2030.
Prior to becoming President and CEO of Kia, Mr. Song held a range of leadership positions, including Head of Global Operations, President of Kia Motors Europe and Head of Kia Motors Corporation Export Planning Group.
Throughout this time, President Song has brought to bear his extensive experience across the automotive value chain as well as his expertise in overseas operations, leading Kia's successful transition throughout a period of significant change in the global automotive industry.
Kia EV3 named 'Best Electric Car'
The Kia EV3 was also named 'Best Electric Car' at the 2025 Autocar Awards. In an exceptionally competitive category, it stood out not only for its impressive 375-mile electric range and fast-charging capability, but also for delivering that performance in a compact, desirable and affordable package.
'The EV3 is the standout addition to the affordable electric car ranks in 2025. It not only extends the design appeal of the statement EV9 into the heart of the electric car market, but also brings with it compelling space and practicality, impressive rapid charging speed, excellent EV drivability and convincing electric range to the party — all for an appealing price,' said Mark Tisshaw, Editor of Autocar.
He continued, 'The EV3 is an electric car customers can afford and one that will really work for them. It's a cracking all-rounder, and very convincing.'
Since its global debut last year, the EV3 has continued to build momentum in markets around the world. It has already received significant international recognition, including the 2025 World Car of the Year and Red Dot's prestigious 'Best of the Best' award. Notably in the UK, the EV3 has seen exceptional success — becoming the best-selling EV in the UK retail market in Q1 and earning the 2025 UK Car of the Year. These achievements follow in the footsteps of its larger sibling, the EV9, which swept the same awards in 2024.
President Song closed the evening by remarking, 'The Kia EV3 being named 'Best Electric Car' at the 2025 Autocar Awards — along with its growing list of accolades — underscores Kia's commitment to innovation. With our Platform Beyond Vehicle (PBV) strategy now underway, and a model lineup soon to span from the highly anticipated EV2 all the way up to the premium EV9, we're well positioned to lead the global shift to electrification.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
TAILG Returns to Jakarta Fair, Deepens Footprint in Indonesia
JAKARTA, Indonesia, June 30, 2025 /PRNewswire/ — On June 19, Indonesia's largest comprehensive exhibition, Jakarta Fair, officially opened at JIExpo in Jakarta. TAILG showcased 11 products and launched on-site test ride experiences, standing out as one of the most prominent two-wheeled electric mobility brands at the expo. User-Oriented, Built for Local Preferences Jakarta Fair Kemayoran runs from June 19 to July 13 at JIExpo in Jakarta, with over 2,550 companies exhibiting across 1,550 booths. The event is expected to generate over 7.5 trillion IDR in transactions. As a global leader in electric two- and three-wheel vehicles, TAILG began localizing operations in Indonesia in 2023. Based on local user needs and preferences, TAILG presented 11 key products at this expo, showcasing strong long range capabilities. The GF52, TAILG's flagship long range model, features a full-coverage airplane-style handlebar, a top speed of 55 km/h, smart cruise control, and a convenient reverse function—making it a popular choice for commuters. Recently, influencer KAYE (TikTok: daffakaye) tested the model in Jakarta traffic, achieving an impressive 102 km on a single charge. The video gained over a million likes and views online. The X51-M, with its mech-style design and lightweight frame, offers a max range of 65 km. Since its launch earlier this year, it has been widely favored by students. Moreover, female-oriented models like GR51, GR52, GE55, and GALAXY EB, boasting eye-catching designs, comfortable seats, and user-friendly handling, perfectly meet the dual demands of practicality and comfort for moms. These features have attracted numerous female users to test-ride on-site. Meanwhile, simple electric models such as JS31, JY32, and JY36, with their lightweight and safe designs, have proven popular among students. Rooted in Indonesia, Committed to Deepening Local Development Since the brand went overseas, TAILG has regarded Indonesia and Vietnam as important benchmark markets for the globalization strategy. Based in Indonesia and radiating to Southeast Asia, TAILG continues to promote localization. In 2024, TAILG opened its office and flagship showroom in Tangerang, followed by the launch of its local factory. It has now established a fully localized system covering R&D, manufacturing, and sales. Centered on Java Island, TAILG has built a sales and service network across major cities, with over 200 branded stores. To further enhance supply chain efficiency and improve local service capacity, TAILG has built an integrated manufacturing base in Indonesia that includes assembly, quality inspection, testing, and logistics. The base follows international quality standards and is equipped with advanced production lines and a comprehensive quality control system to ensure high product quality and efficient delivery. As TAILG expands globally, it continues to partner with world-class brands to offer users smarter and more advanced long range products. As the first electric vehicle brand to form a global strategic partnership with BYD, TAILG is actively introducing BYD's small-capacity blade battery solutions, known for their high safety, long life, and strong performance. Rooted in Indonesia and expanding globally, TAILG's strength in products and branding has been widely recognized by users at the JFK Expo. In the future, TAILG will continue to strengthen its long range product lineup, build a strong reputation for endurance performance, and bring Indonesian users a greener, more convenient, and safer riding experience. YouTube video link:
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ — Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. The event drew over 500 participants, including leading oncology key opinion leaders (KOLs), principal investigators, analysts, and global investors, signaling strong engagement with Innovent's transformative vision for the future of oncology. 'Over the past decade, Innovent has been at the forefront of China's biopharmaceutical evolution—pioneering the PD-1 immunotherapy era and building China's leading oncology brand, with over 3 million cancer patients treated with our therapies,' said Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent. 'We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innovation of next-generation IO and next-generation ADC. Our recent presence at the 2025 ASCO with eight oral presentations highlights the strength and global competitiveness of our R&D. But this is only the beginning. With a clear vision to advance at least five pipeline assets into MRCT Phase 3 by 2030, we are committed to delivering innovative, high-quality, and accessible cancer treatments to patients worldwide.' Dual Innovation to Unlock the Future of Oncology: Next-gen IO + Next-gen ADC At the core of Innovent's oncology strategy lies the dual engines of next-generation immunotherapy (IO) and next-generation antibody-drug conjugates (ADC), supported by deep insights in cancer biology and differentiated technology platforms. 'We are harnessing deep cancer biology insights, advanced antibody and protein engineering, and differentiated ADC linker-payload technologies to develop broader-spectrum, more potent, and less toxic therapies aimed at transforming the oncology treatment paradigm,' said Dr. Zhou Hui, SVP of Innovent Oncology R&D. 'Our strategy is designed to target some of the toughest challenges in cancer care, including drug resistance, cold tumors, and improve the efficacy of current IO treatment, while bringing new hope to patients worldwide.' Global R&D Roadmap: a Clear, Stepwise Development Strategy Innovent's pipeline is guided by a rational, phased IO+ADC combination strategy designed to address tumor heterogeneity and immune escape, evolving through three stages: Next-gen IO + Chemotherapy: to redefine the IO cornerstone Next-gen IO + mAb-ADC / bispecific ADC: to cover expansive tumor types and treatment lines Next-gen IO + Dual-Payload ADC (dpADC): to unlock full potential of IO+ ADC synergy, and reshape cancer treatment Currently its oncology pipeline features nearly 10 next-generation molecules in global development, with multi-regional trials actively underway in the U.S., EU, and Asia. The company also continues to invest in global R&D infrastructure, supported by R&D hubs in Shanghai and San Francisco and antibody and ADC manufacturing capacity exceeding 140,000L. Innovent is rapidly expanding its global innovation footprint, with a 2030 goal to advance at least five pipeline assets into global MRCT Phase 3 trials. Key potential candidates includes: IBI343: innovative CLDN18.2 ADC with site-specific conjugation and a TOPO1 inhibitor payload, demonstrating significant survival benefits in both GC and PDAC IBI363: PD-1/IL-2α-bias fusion protein as next-gen IO to redefine cancer treatment and expand the boundaries of IO responsiveness IBI3009: DLL3 ADC in collaboration with Roche IBI3003: tri-specific T-cell engager targeting BCMA/GPRC5D/CD3 for multiple myeloma IBI3001: EGFR/B7H3 ADC with two synergetic targets covering multiple potential indications IBI3020: CEACAM5 dual-payload ADC as globally the first to enter clinical phase IBI363: Next-Gen IO Redefining Cancer Immunotherapy IBI363 is a global first-in-class PD-1/IL-2α-bias fusion protein, featuring a differentiated molecular design and a dual immune activation mechanism. Emerging clinical data strongly support its mechanism of action in reinvigorating and expanding tumor-specific T cells (TSTs). At ASCO 2025, IBI363 demonstrated breakthrough potential in three hard-to-treat tumor types, with a long tailing effect in prolonged survival benefits: Immune-resistant NSCLC (squamous & Adeno): boosted response rate and extended PFS reflects strong immune activation; median overall survival (mOS) up to 17.5 months in 1.5 mg dose cohorts, 12-month OS rate exceeding 70% for 3 mg dose cohorts, and benefit observed even in PD-L1 low expressers Later-line CRC (3L+): mOS of 16.1 months in monotherapy and only 17.8% OS events occurred in combination with bevacizumab with 9.4 months follow-up, outperforming historical benchmarks Immune-resistant melanoma (mucosal/acral subtypes): confirmed overall response rate (cORR) 23%, median duration of response (mDoR) 14 months, and median OS 14.7 months, showing unprecedented positive response and a long-lasting immunologic tailing effect With two Breakthrough Therapy Designations from the NMPA CDE, two Fast Track Designations from the FDA, IBI363 is advancing rapidly toward registrational development. The first head-to-head trial vs. pembrolizumab in mucosal and acral melanoma was initiated. Meanwhile, IBI363 is in preparation for registrational trails in IO-treated squamous NSCLC, and third-line MSS colorectal cancer. Additional trails for first-line and other solid tumors also under exploration in ongoing PoC studies. High-Potency, Low-toxicity ADC Platforms Synergizing with IO for Broad Indication Coverage Innovent is rapidly advancing its next-gen ADC pipeline, including: IBI343 (CLDN18.2 ADC): first in PDAC to demonstrate long-term survival benefits (mOS 12.1 months in 2L) IBI3001 (EGFR/B7H3 ADC): dual-targeted ADC with broad potential in solid tumors IBI3020 (CEACAM5 dual payload ADC): designed for high efficacy and low toxicity in treatment-resistant tumors These programs leverage proprietary payloads and linkers, optimized for lower toxicity and high potency, and are poised to synergize with Innovent's IO agents to address broader and deeper indications. Innovent Academy: R&D Engine to Drive Global Innovation Innovent Academy is the company's discovery engine for driving global innovation. The Academy continues to expand its platforms in IO, ADC, T-cell engagers, and cytokines, firmly establishing its leadership in next-gen oncology discovery and translational science to generate 6–8 novel molecules per year. Specifically, for next-gen IO and next-gen ADC dual upgradation, Innovent Academy focuses on: diversified antitumor mechanisms to integrate TME modulation and optimize IO efficacy; dual targeting approaches to overcome tumor heterogeneity and drug resistance. This framework allows Innovent to systematically escalate efficacy and broaden tumor applicability, laying the foundation for first-in-class and best-in-class combination regimens for cancer treatments. Catalyzing China's Role in Global Oncology Innovation Leading oncology KOLs and principal investigators (PIs) delivered keynote speeches, reflecting on a pivotal moment for China's biotech industry. They emphasized that China's innovation, which is driven by rising translational capabilities, expanding global talent pools, and patient-centric trial execution, has entered a 'Deepseek' moment, one where Chinese-discovered drugs can lead global standards, not just follow them. 'What we're witnessing is a profound shift,' said one keynote speaker. 'Innovent's next-generation IO programs like IBI363, with a clear global-first design, and ADC platforms targeting previously untreatable populations, show that Chinese biotech is poised to influence—not just participate in—the next global oncology paradigm.' The enthusiastic response from investors and KOLs underscores growing confidence in China-originated oncology innovation and reaffirms Innovent's position as it enters a new era of global innovation with a vision to become a global premier biopharmaceutical leader. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications (NDA) under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Otis Provides The Kross in Ho Chi Minh City With Smart Mobility Systems
For exceptional passenger experience, proven innovation and seamless building system integration HO CHI MINH CITY, Vietnam, June 30, 2025 /PRNewswire/ — Otis (NYSE: OTIS), the world's leading elevator and escalator manufacturing, installation and service company, will install advanced technology and connected vertical mobility solutions for The Kross, a premium 39-story mixed-use building in the heart of Ho Chi Minh's central business district. Otis to complete installation of 7 SkyRise® and 9 Gen3™ elevator systems in The Kross by 2026 Otis will maintain The Kross' vertical mobility systems through 2028. 'We are delighted to contribute to this prestigious development that will redefine Ho Chi Minh City's urban skyline,' said Manivannan K., Managing Director of Otis Vietnam and Cambodia. 'By equipping the project with Otis' most advanced high-rise elevator and cutting-edge digital technologies, we are delivering a predictive, proactive, and transparent view of elevator operations, making it easier for our customers to manage, and enhancing their passengers' experiences.' What Otis systems will be in The Kross, Ho Chi Minh City? The Gen3 elevator system, launched in Vietnam in 2024, is digitally connected. It enables real-time monitoring, predictive maintenance, and seamless building integration. This enhances efficiency, improves safety, and elevates the customer experience The flexible SkyRise system – available in a range of speeds and rises up to 900m – is the ideal choice for skyscrapers, for example at One Za'abeel and the New Bund Center The Kross will be integrated with Compass® 360 elevator destination management. Compass 360 is an intelligent dispatching technology that groups passengers' by destinations and will reduce travelling time up to 50% in peak travel periods An EMS PanoramaTM 2.0 elevator management system will allow building owners to monitor, control, report on and manage a full range of operational-critical functions About Otis Otis gives people freedom to connect and thrive in a taller, faster, smarter world. The global leader in the manufacture, installation and servicing of elevators and escalators, we move 2.4 billion people a day and maintain approximately 2.4 million customer units worldwide – the industry's largest Service portfolio. You'll find us in the world's most iconic structures, as well as residential and commercial buildings, transportation hubs and everywhere people are on the move. Headquartered in Connecticut, USA, Otis is 72,000 people strong, including 44,000 field professionals, all committed to manufacturing, installing and maintaining products to meet the diverse needs of our customers and passengers in more than 200 countries and territories. To learn more, visit and follow us on LinkedIn, Instagram and Facebook @OtisElevatorCo.
